Story
Braveheart Bio Files for $318.8 Million IPO to Fund Heart Drug Trials
Summary
Clinical-stage biopharmaceutical firm Braveheart Bio Inc. is seeking to raise up to $318.8 million in an initial public offering to advance its late-stage drug for hypertrophic cardiomyopathy, a common heart condition.
Braveheart Bio Inc., a clinical-stage biopharmaceutical company, announced plans to raise as much as $318.8 million in an initial public offering. The proposed listing would support the development of its lead drug candidate for treating a prevalent genetic heart disease.
Offering Details
According to a filing with the U.S. Securities and Exchange Commission on Thursday, the San Francisco-based company plans to offer 18.8 million shares at a price range of $15 to $17 each. At the top end of this range, the IPO would give Braveheart Bio a market valuation of approximately $1.2 billion.
The company has applied to list its common stock on the Nasdaq Global Market under the ticker symbol BRVE. The offering is being managed by a syndicate of joint bookrunners including Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel, and Cantor.
Use of Proceeds and Pipeline
Braveheart Bio is focused on developing BHB-1893, a next-generation oral cardiac myosin inhibitor for treating obstructive and non-obstructive hypertrophic cardiomyopathy. The company in-licensed the compound from its originator, Jiangsu Hengrui Pharmaceuticals Co., Ltd., in September 2025.
AdProceeds from the IPO are expected to fund crucial late-stage clinical trials:
- LIONHEART-HCM: A global Phase 3 trial for obstructive hypertrophic cardiomyopathy, set to begin in the second half of 2026. Interim results are anticipated in the second half of 2027.
- NOBLEHEART-HCM: A global Phase 3 trial for the non-obstructive form of the disease, planned to start in the first half of 2027.
Investor Backing
The company, which is backed by venture capital firm a16z, has also received a significant signal of institutional interest. Fidelity Management & Research Company LLC has provided a non-binding indication of interest to purchase up to $75 million worth of shares at the IPO price, according to the filing.
Read next
More on Stocks
CarMax Stock Surges on Strong Earnings Beat and Sales Rebound
CarMax reported fiscal second-quarter results that far exceeded analyst expectations, driven by a 13% jump in same-store sales and plans to resume its share buyback program.
Netflix Stock Gains After Deutsche Bank Upgrades to 'Buy'
Shares of the streaming giant rose after Deutsche Bank upgraded the stock to 'Buy' from 'Hold,' setting a $95 price target and citing a valuation opportunity following a prolonged selloff.
Amazon, GoodRx Prescription Subscriptions Gain Traction Amid Rising US Healthcare Costs
Amazon and GoodRx are seeing significant growth in their prescription drug subscription services as consumers seek alternatives to rising insurance premiums and out-of-pocket expenses.
SEC Proposes Scaling Back Sarbanes-Oxley Auditor Requirements
The U.S. Securities and Exchange Commission plans to reduce the number of companies required to have external auditors verify internal financial controls, a key post-Enron investor protection.